Treatment of Molluscum Contagiosum
Primary Treatment Recommendation
Physical removal methods—including curettage, simple excision, excision with cautery, or cryotherapy with liquid nitrogen—are the first-line treatments for molluscum contagiosum, particularly for symptomatic lesions, multiple lesions, or those near the eyes causing conjunctivitis. 1, 2, 3
Treatment Algorithm by Clinical Scenario
For Immunocompetent Children and Adults
Active treatment is indicated for:
- Symptomatic lesions (painful, itchy, or inflamed) 1, 3
- Multiple lesions (to prevent autoinoculation and transmission) 1, 3
- Periocular lesions with associated conjunctivitis 1, 2, 3
- Patient/parent preference to avoid prolonged infectivity 1
Watchful waiting is reasonable for:
- Asymptomatic lesions 3
- Limited number of lesions 3
- No periocular involvement 3
- Lesions typically resolve spontaneously in 6-12 months, though can persist up to 4-5 years 1, 3
First-Line Physical Treatment Options
Cryotherapy with liquid nitrogen:
- Achieves complete response in approximately 93% of cases 1, 3
- Apply until visible freezing extends slightly beyond lesion margin into normal skin 1
- Major caveat: Risk of postinflammatory hyperpigmentation (most common adverse effect, may persist 6-12 months) or scarring, particularly concerning for facial lesions or darker skin tones 1, 3
- Avoid treating sensitive areas (eyelids, lips, nose, ears) due to higher complication risk 1
Curettage, excision, or excision with cautery:
First-Line Chemical Treatment Options
10% potassium hydroxide solution:
- The American Academy of Pediatrics recommends this as first-line chemical treatment 1, 3
- Similar efficacy to cryotherapy (86.6% complete response vs 93.3% for cryotherapy) 1
- Better cosmetic results with lower risk of hyperpigmentation compared to cryotherapy 1, 3
Cantharidin:
- Shows effectiveness in observational studies, though randomized controlled trial evidence is limited 1
- Practical option when available 4
Critical Treatment Principles
Identify and treat ALL lesions, including nascent ones:
- Failure to treat early/small lesions is a common cause of recurrence 1, 2
- Reducing viral load allows the host immune response to eliminate residual virus 1, 2
- Examine carefully for nascent lesions during initial treatment 1
For periocular lesions with conjunctivitis:
- Physical removal is imperative to resolve conjunctivitis 1, 2
- Conjunctivitis may require several weeks to resolve after lesion elimination 1, 2
- Monitor for resolution at follow-up 1, 2
Special Populations
Immunocompromised Patients
Multiple large lesions with minimal inflammation should prompt screening for immunocompromised state 1, 2
For extensive or recalcitrant disease:
- Consider referral to dermatology 1, 2
- May require alternative therapies (cidofovir, interferon) in severely immunosuppressed patients 5
Children Under 2 Years
Salicylic acid is contraindicated due to risk of systemic toxicity 3
Pregnant Patients
Physical procedures (cryotherapy, curettage) are safe to use 5
Treatments to AVOID
Imiquimod:
- The FDA explicitly states that imiquimod cream failed to demonstrate efficacy in two randomized, vehicle-controlled trials in 702 pediatric subjects with molluscum contagiosum 6
- Complete clearance rates were 24% with imiquimod vs 26-28% with vehicle (no benefit) 6
- The American Academy of Pediatrics explicitly states imiquimod should not be used 1, 3, 6
H2 blockers (ranitidine, cimetidine):
Follow-Up and Prevention
Follow-up is not usually necessary unless:
Prevention measures:
- Hand hygiene with alcohol-based disinfectant or soap and water is the most important prevention method 1, 3
- Avoid sharing towels, clothing, and personal items 1, 3
- Cover all lesions with waterproof bandages if water exposure is unavoidable 1, 3
- Avoid skin contact with infected individuals 1
Common Pitfalls
- Missing nascent lesions during initial treatment leads to recurrence 1
- Underestimating the need to treat periocular lesions, which require active treatment to prevent ocular complications 1
- Using imiquimod despite clear evidence of inefficacy 1, 3, 6
- Not considering immunocompromised state when seeing extensive disease with minimal inflammation 1, 2